UCB Pharma GmbH

Germany

Back to Profile

1-90 of 90 for UCB Pharma GmbH and 1 subsidiary Sort by
Query
Aggregations
IP Type
        Patent 59
        Trademark 31
Jurisdiction
        World 41
        United States 30
        Europe 11
        Canada 8
Owner / Subsidiary
[Owner] UCB Pharma GmbH 89
UCB Manufacturing Ireland Limited 1
Date
2023 1
2022 3
2021 2
2020 2
Before 2020 82
IPC Class
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links 15
A61K 9/70 - Web, sheet or filament bases 12
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings 11
C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring 9
C07D 471/04 - Ortho-condensed systems 8
See more
NICE Class
05 - Pharmaceutical, veterinary and sanitary products 24
41 - Education, entertainment, sporting and cultural services 10
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services 10
16 - Paper, cardboard and goods made from these materials 7
42 - Scientific, technological and industrial services, research and design 5
See more
Status
Pending 6
Registered / In Force 84

1.

Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides

      
Application Number 18219417
Status Pending
Filing Date 2023-07-07
First Publication Date 2023-11-02
Owner UCB Pharma GmbH (Germany)
Inventor
  • Mueller, Christa E.
  • Pegurier, Cécile
  • Deligny, Michael Louis Robert
  • El-Tayeb, Ali
  • Hockemeyer, Joerg
  • Ledecq, Marie
  • Mercier, Joël
  • Provins, Larurent
  • Boshta, Nader M.
  • Bhattarai, Sanjay
  • Namasivayam, Vigneshwaran
  • Funke, Mario
  • Schwach, Lukas
  • Gollos, Sabrina
  • Von Laufenberg, Daniel
  • Barré, Anaïs

Abstract

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

IPC Classes  ?

  • C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 421/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 487/04 - Ortho-condensed systems
  • C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

2.

N-(PHENYL)-Indole-3-Sulfonamide Derivatives And Related Compounds As GPR17 Modulators For Treating CNS Disorders Such As Multiple Sclerosis

      
Application Number 17619631
Status Pending
Filing Date 2020-06-16
First Publication Date 2022-09-22
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Pegurier, Cécile
  • Lovera, Silvia
  • Mueller, Christa E.
  • Hockemeyer, Joerg
  • Rashed, Mahmoud
  • El-Tayeb, Ali
  • Zhang, Yong-Qiang

Abstract

Disclosed are N-(phenyl)-1H-indole-3-sulfonanmide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g. the N-pyridin-2-yl and the N-pyridin-3-yl analogues thereof). The present compounds have GPR17 modulating properties which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating disorders such as multiple sclerosis. Disclosed are N-(phenyl)-1H-indole-3-sulfonanmide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g. the N-pyridin-2-yl and the N-pyridin-3-yl analogues thereof). The present compounds have GPR17 modulating properties which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating disorders such as multiple sclerosis.

IPC Classes  ?

  • C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 471/04 - Ortho-condensed systems

3.

Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides

      
Application Number 17568824
Grant Number 11820746
Status In Force
Filing Date 2022-01-05
First Publication Date 2022-04-28
Grant Date 2023-11-21
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Mueller, Christa E.
  • Pegurier, Cécile
  • Deligny, Michael Louis Robert
  • El-Tayeb, Ali
  • Hockemeyer, Joerg
  • Ledecq, Marie
  • Mercier, Joël
  • Provins, Larurent
  • Boshta, Nader M.
  • Bhattarai, Sanjay
  • Namasivayam, Vigneshwaran
  • Funke, Mario
  • Schwach, Lukas
  • Gollos, Sabrina
  • Von Laufenberg, Daniel
  • Barré, Anaïs

Abstract

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

IPC Classes  ?

  • C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 421/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 487/04 - Ortho-condensed systems
  • C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

4.

Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides

      
Application Number 17506331
Grant Number 12071404
Status In Force
Filing Date 2021-10-20
First Publication Date 2022-02-17
Grant Date 2024-08-27
Owner UCB Pharma GmbH (Germany)
Inventor
  • Mueller, Christa E.
  • Pegurier, Cécile
  • Deligny, Michael Louis Robert
  • El-Tayeb, Ali
  • Hockemeyer, Joerg
  • Ledecq, Marie
  • Mercier, Joël
  • Provins, Laurent
  • Boshta, Nader M.
  • Bhattarai, Sanjay
  • Namasivayam, Vigneshwaran
  • Funke, Mario
  • Schwach, Lukas
  • Gollos, Sabrina
  • Von Laufenberg, Daniel
  • Barré, Anaïs

Abstract

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

IPC Classes  ?

  • C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 421/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 487/04 - Ortho-condensed systems
  • C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

5.

Substituted alkoxypyridinyl indolsulfonamides

      
Application Number 17058567
Grant Number 11976056
Status In Force
Filing Date 2019-06-19
First Publication Date 2021-07-15
Grant Date 2024-05-07
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Pegurier, Cecile
  • Provins, Laurent
  • Isin, Emre M.
  • Ledecq, Marie

Abstract

The present application relates to alkoxy-substituted pyridinyl indolsulfonamides. The compounds are negative GPR17 modulators and have utility in the treatment of various GPR17 associated disorders.

IPC Classes  ?

  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

6.

Pyridinyl and pyrazinyl-(asa)indolsulfonamides

      
Application Number 17058845
Grant Number 11939319
Status In Force
Filing Date 2019-06-18
First Publication Date 2021-07-08
Grant Date 2024-03-26
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Pegurier, Cecile
  • Provins, Laurent
  • Cardenas, Alvaro
  • Ledecq, Marie
  • Mueller, Christa E.
  • Hockemeyer, Joerg
  • El-Tayeb, Ali
  • Boshta, Nader
  • Rashed, Mahmoud

Abstract

The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.

IPC Classes  ?

  • C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 471/04 - Ortho-condensed systems

7.

N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS

      
Application Number EP2020066560
Publication Number 2020/254289
Status In Force
Filing Date 2020-06-16
Publication Date 2020-12-24
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Pegurier, Cécile
  • Lovera, Silvia
  • Mueller, Christa E.
  • Hockemeyer, Joerg
  • Rashed, Mahmoud
  • El-Tayeb, Ali
  • Zhang, Yong-Qiang

Abstract

Disclosed are N-(phenyl)-lH-indole-3-sulfonamide and N-(phenyl) -1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g. the N-pyridin-2-yl and the N-pyridin-3-yl analogues thereof). The present compounds have GPR17 modulating properties which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating disorders such as multiple sclerosis.

IPC Classes  ?

  • C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D 471/04 - Ortho-condensed systems
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
  • A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

8.

N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS

      
Document Number 03137091
Status Pending
Filing Date 2020-06-16
Open to Public Date 2020-12-24
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Pegurier, Cecile
  • Lovera, Silvia
  • Mueller, Christa E.
  • Hockemeyer, Joerg
  • Rashed, Mahmoud
  • El-Tayeb, Ali
  • Zhang, Yong-Qiang

Abstract

Disclosed are N-(phenyl)-lH-indole-3-sulfonamide and N-(phenyl) -1 H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives of formula I substituted at the 1- and 6-positions of the 1H-indole or 1H-pyrrolo[2,3-b]pyridine moiety, as well as structurally related compounds (e.g. the N-pyridin-2-yl and the N-pyridin-3-yl analogues thereof). The present compounds have GPR17 modulating properties which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating disorders such as multiple sclerosis.

IPC Classes  ?

  • C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 471/04 - Ortho-condensed systems

9.

PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES

      
Document Number 03100795
Status Pending
Filing Date 2019-06-18
Open to Public Date 2019-12-26
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Pegurier, Cecile
  • Provins, Laurent
  • Cardenas, Alvaro
  • Ledecq, Marie
  • Mueller, Christa E.
  • Hockemeyer, Joerg
  • El-Tayeb, Ali
  • Boshta, Nader
  • Rashed, Mahmoud

Abstract

The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.

IPC Classes  ?

  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61P 25/00 - Drugs for disorders of the nervous system
  • C07D 471/04 - Ortho-condensed systems

10.

SUBSTITUTED ALKOXYPYRIDINYL INDOLSULFONAMIDES

      
Document Number 03101086
Status Pending
Filing Date 2019-06-19
Open to Public Date 2019-12-26
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Pegurier, Cecile
  • Provins, Laurent
  • Isin, Emre M.
  • Ledecq, Marie

Abstract

The present application relates to alkoxy-substituted pyridinyl indolsulfonamides. The compounds are negative GPR17 modulators and have utility in the treatment of various GPR17 associated disorders.

IPC Classes  ?

  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61P 25/00 - Drugs for disorders of the nervous system

11.

PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES

      
Application Number EP2019065967
Publication Number 2019/243303
Status In Force
Filing Date 2019-06-18
Publication Date 2019-12-26
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Pegurier, Cécile
  • Provins, Laurent
  • Cardenas, Alvaro
  • Ledecq, Marie
  • Mueller, Christa E.
  • Hockemeyer, Joerg
  • El-Tayeb, Ali
  • Boshta, Nader
  • Rashed, Mahmoud

Abstract

The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.

IPC Classes  ?

  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 471/04 - Ortho-condensed systems
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

12.

SUBSTITUTED ALKOXYPYRIDINYL INDOLSULFONAMIDES

      
Application Number EP2019066148
Publication Number 2019/243398
Status In Force
Filing Date 2019-06-19
Publication Date 2019-12-26
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Pegurier, Cécile
  • Provins, Laurent
  • Isin, Emre M.
  • Ledecq, Marie

Abstract

The present application relates to alkoxy-substituted pyridinyl indolsulfonamides. The compounds are negative GPR17 modulators and have utility in the treatment of various GPR17 associated disorders.

IPC Classes  ?

  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

13.

Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides

      
Application Number 16474245
Grant Number 11345662
Status In Force
Filing Date 2017-12-27
First Publication Date 2019-11-14
Grant Date 2022-05-31
Owner UCB Pharma GmbH (Germany)
Inventor
  • Mueller, Christa E.
  • Pegurier, Cécile
  • Deligny, Michael Louis Robert
  • El-Tayeb, Ali
  • Hockemeyer, Joerg
  • Ledecq, Marie
  • Mercier, Joël
  • Provins, Laurent
  • Boshta, Nader M.
  • Bhattarai, Sanjay
  • Namasivayam, Vigneshwaran
  • Funke, Mario
  • Schwach, Lukas
  • Gollos, Sabrina
  • Von Laufenberg, Daniel
  • Barré, Anaïs

Abstract

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

IPC Classes  ?

  • C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D 307/82 - Benzo [b] furansHydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 421/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 487/04 - Ortho-condensed systems
  • C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

14.

Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine

      
Application Number 15982744
Grant Number 10350174
Status In Force
Filing Date 2018-05-17
First Publication Date 2018-09-20
Grant Date 2019-07-16
Owner
  • UCB Pharma GmbH (Germany)
  • LTS Lohmann Therapie-Systeme AG (Germany)
Inventor
  • Wolff, Hans-Michael
  • Arth, Christoph
  • Quere, Luc
  • Müller, Walter

Abstract

The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

IPC Classes  ?

  • A61K 9/70 - Web, sheet or filament bases
  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings

15.

(AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES

      
Application Number EP2017084602
Publication Number 2018/122232
Status In Force
Filing Date 2017-12-27
Publication Date 2018-07-05
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Mueller, Christa E.
  • Pegurier, Cécile
  • Deligny, Michael Louis Robert
  • El-Tayeb, Ali
  • Hockemeyer, Joerg
  • Ledecq, Marie
  • Mercier, Joël
  • Provins, Laurent
  • Boshta, Nader M.
  • Bhattarai, Sanjay
  • Namasivayam, Vigneshwaran
  • Funke, Mario
  • Schwach, Lukas
  • Gollos, Sabrina
  • Von Laufenberg, Daniel
  • Barré, Anaïs

Abstract

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

IPC Classes  ?

  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 421/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 471/04 - Ortho-condensed systems
  • C07D 493/04 - Ortho-condensed systems
  • C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D 209/90 - Benzo [c, d] indolesHydrogenated benzo [c, d] indoles
  • A61P 25/16 - Anti-Parkinson drugs
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

16.

(AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES

      
Document Number 03045244
Status Pending
Filing Date 2017-12-27
Open to Public Date 2018-07-05
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Mueller, Christa E.
  • Pegurier, Cecile
  • Deligny, Michael Louis Robert
  • El-Tayeb, Ali
  • Hockemeyer, Joerg
  • Ledecq, Marie
  • Mercier, Joel
  • Provins, Laurent
  • Boshta, Nader M.
  • Bhattarai, Sanjay
  • Namasivayam, Vigneshwaran
  • Funke, Mario
  • Schwach, Lukas
  • Gollos, Sabrina
  • Von Laufenberg, Daniel
  • Barre, Anais

Abstract

Disclosed are compounds of Formula 1-2,and pharmaceutically acceptable salts, solvates and isotopes thereof, with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

IPC Classes  ?

  • C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
  • A61P 25/16 - Anti-Parkinson drugs
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D 209/90 - Benzo [c, d] indolesHydrogenated benzo [c, d] indoles
  • C07D 333/62 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 421/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
  • C07D 471/04 - Ortho-condensed systems
  • C07D 493/04 - Ortho-condensed systems

17.

Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine

      
Application Number 15884587
Grant Number 10130589
Status In Force
Filing Date 2018-01-31
First Publication Date 2018-05-31
Grant Date 2018-11-20
Owner
  • UCB Pharma GmbH (Germany)
  • LTS Lohmann Therapie-Systeme AG (Germany)
Inventor
  • Wolff, Hans-Michael
  • Arth, Christoph
  • Quere, Luc
  • Müller, Walter

Abstract

The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

IPC Classes  ?

  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61K 9/70 - Web, sheet or filament bases

18.

AxSpALive

      
Application Number 1379522
Status Registered
Filing Date 2017-05-19
Registration Date 2017-05-19
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 09 - Scientific and electric apparatus and instruments
  • 35 - Advertising and business services
  • 41 - Education, entertainment, sporting and cultural services
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, recording discs; compact discs, DVDs and other digital recording media; mechanisms for coin-operated apparatus; cash registers, calculating machines, data processing equipment, computers; computer software; fire-extinguishing apparatus; database and application software for medical purposes. Advertising; business management; business administration; office functions; product marketing for the pharmaceutical industry. Education; providing of training; entertainment; sporting and cultural activities; publication of information, in particular of information in the pharmaceutical and medical sectors, in particular via the Internet. Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; scientific and technological services, in particular for the pharmaceutical and medical sectors. Medical services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services; medical consultancy and medical coaching for patients; medical consultancy for doctors.

19.

PsALive

      
Application Number 1380382
Status Registered
Filing Date 2017-05-19
Registration Date 2017-05-19
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 09 - Scientific and electric apparatus and instruments
  • 35 - Advertising and business services
  • 41 - Education, entertainment, sporting and cultural services
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, recording discs; compact discs, DVDs and other digital recording media; mechanisms for coin-operated apparatus; cash registers, calculating machines, data processing equipment, computers; computer software; fire-extinguishing apparatus; database and application software for medical purposes. Advertising; product marketing for the pharmaceutical industry; all of the aforesaid services only in relation to products for individuals suffering from psoriatic arthritis, provided via software. Publication of information, in particular of information in the pharmaceutical and medical sectors, in particular via the Internet; all of the aforesaid services only in relation to goods or matters in connection with psoriatic arthritis. Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; scientific and technological services, in particular for the pharmaceutical and medical sectors. Medical services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services; medical consultancy and medical coaching for patients; medical consultancy for doctors.

20.

PsALive

      
Application Number 016269466
Status Registered
Filing Date 2017-01-20
Registration Date 2017-05-09
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 09 - Scientific and electric apparatus and instruments
  • 35 - Advertising and business services
  • 41 - Education, entertainment, sporting and cultural services
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; Apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; Apparatus for recording, transmission or reproduction of sound or images; Magnetic data carriers, recording discs; Compact discs, DVDs and other digital recording media; Mechanisms for coin-operated apparatus; Cash registers, calculating machines, data processing equipment, computers; Computer software; Fire-extinguishing apparatus; Database and application software for medical purposes. Advertising; Product marketing for the pharmaceutical industry; All of the aforesaid services only in relation to products for individuals suffering from psoriatic arthritis, provided via software. Publication of information, in particular of information in the pharmaceutical and medical sectors, In particular via the Internet; All of the aforesaid services only in relation to goods or matters in connection with psoriatic arthritis. Scientific and technological services and research and design relating thereto; Industrial analysis and research services; Design and development of computer hardware and software; Services in this class, in particular for the pharmaceutical and medical sectors. Medical services; Hygienic and beauty care for human beings or animals; Agriculture, horticulture and forestry services; Medical consultancy and medical coaching for patients; Medical consultancy for doctors.

21.

AxSpALive

      
Application Number 016269482
Status Registered
Filing Date 2017-01-20
Registration Date 2017-05-08
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 09 - Scientific and electric apparatus and instruments
  • 35 - Advertising and business services
  • 41 - Education, entertainment, sporting and cultural services
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; Apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; Apparatus for recording, transmission or reproduction of sound or images; Magnetic data carriers, recording discs; Compact discs, DVDs and other digital recording media; Mechanisms for coin-operated apparatus; Cash registers, calculating machines, data processing equipment, computers; Computer software; Fire-extinguishing apparatus; Database and application software for medical purposes. Advertising; Business management; Business administration; Office functions; Product marketing for the pharmaceutical industry. Education; Providing of training; Entertainment; Sporting and cultural activities; Publication of information, in particular of information in the pharmaceutical and medical sectors, In particular via the Internet. Scientific and technological services and research and design relating thereto; Industrial analysis and research services; Design and development of computer hardware and software; Services in this class, in particular for the pharmaceutical and medical sectors. Medical services; Hygienic and beauty care for human beings or animals; Agriculture, horticulture and forestry services; Medical consultancy and medical coaching for patients; Medical consultancy for doctors.

22.

neureca

      
Application Number 015197528
Status Registered
Filing Date 2016-03-09
Registration Date 2016-07-19
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 41 - Education, entertainment, sporting and cultural services
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Providing educational services and resources via a website to health care providers and patients in the field of central nervous system disorders. Pharmaceutical advice on the application and / or the use of drugs and / or health care products for the treatment of central nervous system disorders.

23.

Neuro Speed Dating

      
Application Number 015059496
Status Registered
Filing Date 2016-02-01
Registration Date 2016-06-14
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 41 - Education, entertainment, sporting and cultural services

Goods & Services

Arranging and Conducting of seminars and workshops in the medical field.

24.

METHOD FOR ADJUSTING THE RELEASE OF ACTIVE AGENT IN A TRANSDERMAL DELIVERY SYSTEM

      
Application Number EP2015061109
Publication Number 2015/177209
Status In Force
Filing Date 2015-05-20
Publication Date 2015-11-26
Owner
  • LTS LOHMANN THERAPIE-SYSTEME AG (Germany)
  • UCB PHARMA GMBH (Germany)
Inventor
  • Emgenbroich, Marco
  • Leonhard, Johannes Josef
  • Wolff, Hans-Michael

Abstract

Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, wherein the inner phase comprises the additive and an active agent dissolved therein, wherein the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, wherein the maintenance of the permeation rate is proportional to the amount of active agent in the biphasic layer.

IPC Classes  ?

25.

TRANSDERMAL DELIVERY SYSTEM INCLUDING AN INTERFACE MEDIATOR

      
Application Number EP2015061112
Publication Number 2015/177212
Status In Force
Filing Date 2015-05-20
Publication Date 2015-11-26
Owner
  • LTS LOHMANN THERAPIE-SYSTEME AG (Germany)
  • UCB PHARMA GMBH (Germany)
Inventor
  • Emgenbroich, Marco
  • Leonhard, Johannes Josef
  • Kassner, Kristina
  • Lappert, Aurélia

Abstract

Transdermal therapeutic system for the transdermal administration of a systemically active agent comprising a self-adhesive layer structure, comprising A) a backing layer, and B) a dried biphasic layer, the dried biphasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and b) an inner phase having a composition comprising at least one active agent, wherein the inner phase forms dispersed deposits in the outer phase, and c) 0.1 % to 3.5% of an interface mediator with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25°C, and and C) optionally an additional skin contact layer.

IPC Classes  ?

  • A61K 9/70 - Web, sheet or filament bases
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61K 47/02 - Inorganic compounds

26.

TRANSDERMAL DELIVERY SYSTEM CONTAINING ROTIGOTINE

      
Application Number EP2015061099
Publication Number 2015/177204
Status In Force
Filing Date 2015-05-20
Publication Date 2015-11-26
Owner
  • LTS LOHMANN THERAPIE-SYSTEME AG (Germany)
  • UCB PHARMA GMBH (Germany)
Inventor
  • Emgenbroich, Marco
  • Klein, Elke
  • Kluth, Heike

Abstract

Transdermal therapeutic system for the transdermal administration of rotigotine containing an therapeutically effective amount of rotigotine base in a self-adhesive layer structure, comprising A) a backing layer, and B) a rotigotine-containing biphasic layer, the bi phasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or a polymer mixture, and b) an inner phase having a composition comprising rotigotine base, wherein the inner phase forms dispersed deposits in the outer phase, and wherein the inner phase comprises i. rotigotine base, and ii. a polymer mixture comprising at least two hydrophilic polymers selected from at least two of the polymer groups: - polyvinylpyrrolidones having a K- Value of at least 80, or from 80 to 200, - polyvinylpyrrolidones having a K- Value of less than 80, or from 10 to 79, - copolymers of vinyl caprolactam, vinylacetate and ethylene glycol, - copolymers of vinylpyrrolidone and vinylacetate, - copolymers of ethylene and vinylacetate, - polyethylene glycols, - polypropylene glycols, - acrylic polymers, - modified celluloses, wherein the polymer mixture in the inner phase is present in an amount sufficient so that said rotigotine base forms a solid solution with the polymer mixture in the inner phase, and C) optionally an additional skin contact layer.

IPC Classes  ?

  • A61K 9/70 - Web, sheet or filament bases
  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings

27.

Anticonvulsant combination therapy

      
Application Number 14674418
Grant Number 09446011
Status In Force
Filing Date 2015-03-31
First Publication Date 2015-07-23
Grant Date 2016-09-20
Owner UCB PHARMA GMBH (Czech Republic)
Inventor Stöhr, Thomas

Abstract

The present invention is directed to a pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation or/and treatment of epileptic seizures.

IPC Classes  ?

  • A61K 31/19 - Carboxylic acids, e.g. valproic acid
  • A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
  • A61K 38/05 - Dipeptides
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
  • A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
  • A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
  • B65D 81/32 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture

28.

PHARMACEUTICAL COMPOSITION COMPRISING LACOSAMIDE AND LEVETIRACETAM

      
Application Number EP2014075904
Publication Number 2015/079010
Status In Force
Filing Date 2014-11-28
Publication Date 2015-06-04
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Thoorens, Benjamin
  • Fadden, Andrew
  • Pinard, René Pierre
  • Robin, Florent
  • Schubert, Martin Alexander
  • Tennigkeit, Frank
  • Cuypers, Serge

Abstract

The present application relates to a fixed dose combination comprising lacosamide and levetiracetam, as well as to dosage regimens including such fixed dose combinations. The fixed dose combinations are suitable for the oral or parenteral treatment of various diseases, including in particular epilepsy and/or epileptic seizures.

IPC Classes  ?

  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
  • A61P 25/08 - AntiepilepticsAnticonvulsants

29.

Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof

      
Application Number 14257611
Grant Number 09309215
Status In Force
Filing Date 2014-04-21
First Publication Date 2014-08-14
Grant Date 2016-04-12
Owner UCB PHARMA GMBH (Germany)
Inventor Meese, Claus

Abstract

The compound of formula (I): is provided. It may be produced by subjecting a compound of formula (IV) to a reduction reaction wherein R represents hydrogen, straight or branched C1-C6 alkyl. This compound is a valuable intermediate which may be used in the synthesis of fesoterodine, tolterodine, its active metabolite, and related compounds.

IPC Classes  ?

  • C07D 311/00 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
  • C07D 311/20 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
  • C07C 213/00 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
  • A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
  • C07C 227/12 - Formation of amino and carboxyl groups

30.

MICRORNAS AS THERAPEUTICS AND BIOMARKERS FOR EPILEPSY

      
Application Number EP2013077836
Publication Number 2014/096418
Status In Force
Filing Date 2013-12-20
Publication Date 2014-06-26
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Danis, Bénédicte
  • Foerch, Patrik
  • Kaminski, Rafal M.
  • Kretschmann, Anita
  • Siegel, Franziska
  • Pfeifer, Alexander

Abstract

The present invention relates to a pharmaceutical composition for use in the treatment or prevention of epilepsy, comprising a means for alleviating or reversing the effect of a dysregulation of a miRNA molecule. The invention further relates to a vaccine for use in the treatment or prevention of epilepsy, to a biomarker or group of biomarkers associated with epilepsy, a composition for diagnosing, detecting, graduating, monitoring or prognosticating epilepsy or a predisposition for epilepsy, a method or assay for diagnosing, detecting, graduating, monitoring or prognosticating epilepsy or a predisposition for epilepsy. Also envisaged is a method for monitoring epilepsy therapy, a method of identifying an individual eligible for an epilepsy therapy, a corresponding diagnostic kit and the use of a biomarker or a group of biomarkers for diagnosing, detecting, graduating, monitoring or prognosticating epilepsy or for identifying pharmaceutically active agents useful in the treatment or prevention of epilepsy.

IPC Classes  ?

  • A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61P 25/08 - AntiepilepticsAnticonvulsants
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
  • A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

31.

MULTI-DAY PATCH FOR THE TRANSDERMAL ADMINISTRATION OF ROTIGOTINE

      
Application Number EP2013003515
Publication Number 2014/079573
Status In Force
Filing Date 2013-11-21
Publication Date 2014-05-30
Owner
  • UCB PHARMA GMBH (Germany)
  • LTS LOHMANN THERAPIE-SYSTEME AG (Germany)
Inventor
  • Cawello, Willi
  • Lappert, Aurelia
  • Kassner, Kristina
  • Wolff, Hans-Michael
  • Müller, Walter
  • Leonhard, Johannes Josef
  • Emgenbroich, Marco

Abstract

The present invention relates to a transdermal therapeutic system, comprising (a) a backing layer, (b) a solvent -based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, wherein the self- adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer, a kit comprising two transdermal therapeutic systems of the present invention as well as a method for the preparation of the transdermal therapeutic system of the present invention. In addition, the present invention relates to a transdermal therapeutic system comprising rotigotine as active ingredient for use in the treatment of patients suffering from Parkinson's disease, Parkinson's plus syndrome, depression, fibromyalgia and the restless-legs syndrome and for use in the treatment or prevention of dopaminergic neuron loss or cognitive disorders by transdermal administration of rotigotine once or twice weekly, wherein the transdermal therapeutic system comprises a backing layer, a solvent -based rotigotine containing self-adhesive matrix layer as well as a release liner and is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.

IPC Classes  ?

  • A61K 9/70 - Web, sheet or filament bases
  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings

32.

Anticonvulsant combination therapy

      
Application Number 14080440
Grant Number 09095557
Status In Force
Filing Date 2013-11-14
First Publication Date 2014-03-27
Grant Date 2015-08-04
Owner UCB PHARMA GMBH (Germany)
Inventor Stöhr, Thomas

Abstract

The present invention is directed to a pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation or/and treatment of epileptic seizures.

IPC Classes  ?

  • A61K 31/19 - Carboxylic acids, e.g. valproic acid
  • A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
  • A61K 38/05 - Dipeptides
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
  • A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
  • A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin

33.

Daily formulation of lacosamide

      
Application Number 13990861
Grant Number 10149818
Status In Force
Filing Date 2011-12-01
First Publication Date 2013-09-26
Grant Date 2018-12-11
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Cawello, Willi
  • Schubert, Martin Alexander

Abstract

A modified release formulation of lacosamide suitable for once-daily administration.

IPC Classes  ?

  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide

34.

TRANSDERMAL THERAPEUTIC SYSTEM WITH A LOW TENDENCY TO SPONTANEOUSLY CRYSTALLIZE

      
Application Number EP2012077046
Publication Number 2013/098390
Status In Force
Filing Date 2012-12-28
Publication Date 2013-07-04
Owner
  • UCB PHARMA GMBH (Germany)
  • LTS LOHMANN THERAPIE-SYSTEME AG (Germany)
Inventor
  • Dzekan, Horst
  • Hoffmann, Hans-Rainer
  • Horstmann, Michael
  • Müller, Walter
  • Wiedersberg, Sandra

Abstract

The invention relates to transdermal therapeutic systems for dispensing a pharmaceutical product, in particular a pharmaceutical product with a low tendency to spontaneously crystallize. The matrix layer or at least one of the matrix layers in said systems contains a silicone hot-melt adhesive, a pharmaceutical product, and particles made of crosslinked polyvinylpyrrolidone. The invention also relates to a method for producing said transdermal therapeutic systems.

IPC Classes  ?

35.

neureca treat. smarter. together.

      
Application Number 011953882
Status Registered
Filing Date 2013-06-18
Registration Date 2013-10-08
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 38 - Telecommunications services
  • 41 - Education, entertainment, sporting and cultural services
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Telecommunications. Education; Providing of training; Entertainment; Sporting and cultural activities. Scientific and technological services and research and design relating thereto; Industrial analysis and research services; Design and development of computer hardware and software. Medical services; Veterinary services; Hygienic and beauty care for human beings or animals; Agriculture, horticulture and forestry services.

36.

Process for the preparation of nitrogen substituted aminotetralins derivatives

      
Application Number 13806378
Grant Number 08981121
Status In Force
Filing Date 2011-06-24
First Publication Date 2013-04-25
Grant Date 2015-03-17
Owner UCB Pharma GmbH (Germany)
Inventor
  • Ates, Celal
  • Schule, Arnaud
  • Palacio, Magali
  • Deutsch, Paul
  • Vasselin, David
  • Carly, Nicolas
  • Phadtare, Ganesh
  • Yerande, Swapnil
  • Delatinne, Jean-Pierre
  • Escudero Hernandez, Maria Luisa
  • Pinilla, Veronique

Abstract

3 are as defined for compound of formula (I).

IPC Classes  ?

  • C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
  • C07B 57/00 - Separation of optically-active organic compounds
  • C07C 213/10 - SeparationPurificationStabilisationUse of additives
  • C07C 217/52 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
  • C07C 271/24 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
  • C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
  • C07C 51/353 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by isomerisationPreparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by change of size of the carbon skeleton
  • C07C 213/00 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
  • C07C 271/02 - Carbamic acidsSalts of carbamic acids
  • C07C 269/08 - SeparationPurificationStabilisationUse of additives
  • C07C 217/54 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
  • C07C 51/41 - Preparation of salts of carboxylic acids by conversion of the acids or their salts into salts with the same carboxylic acid part

37.

ROTIGOTINE IN THE TREATMENT OF HEMISPATIAL NEGLECT AND OTHER DEFICITS FOLLOWING STROKE

      
Application Number EP2012003477
Publication Number 2013/026547
Status In Force
Filing Date 2012-08-16
Publication Date 2013-02-28
Owner UCB PHARMA GMBH (Germany)
Inventor Husain, Masud

Abstract

The present invention relates to the use of rotigotine for the effective treatment of a condition or disorder selected from neglect, stroke, conditions associated with stroke and/or following stroke. The invention also relates to a rotigotine-containing pharmaceutical composition, like a transepicutaneous pharmaceutical composition especially in the form of a transdermal therapeutic System (TTS).

IPC Classes  ?

  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61K 9/70 - Web, sheet or filament bases
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

38.

Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine

      
Application Number 13515067
Grant Number 09925150
Status In Force
Filing Date 2010-12-22
First Publication Date 2012-12-20
Grant Date 2018-03-27
Owner
  • LTS Lohmann Therapie-Systeme AG (Germany)
  • UCB Pharma GmbH (Germany)
Inventor
  • Wolff, Hans-Michael
  • Arth, Christoph
  • Quere, Luc
  • Müller, Walter

Abstract

The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

IPC Classes  ?

  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61K 9/70 - Web, sheet or filament bases

39.

FORMULATION OF LACOSAMIDE

      
Application Number EP2011006026
Publication Number 2012/084126
Status In Force
Filing Date 2011-12-01
Publication Date 2012-06-28
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Cawello, Willi
  • Schubert, Martin, Alexander

Abstract

A modified release formulation of lacosamide.

IPC Classes  ?

  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61P 25/08 - AntiepilepticsAnticonvulsants
  • A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

40.

ONCE DAILY FORMULATION OF LACOSAMIDE

      
Application Number EP2011006027
Publication Number 2012/072256
Status In Force
Filing Date 2011-12-01
Publication Date 2012-06-07
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Cawello, Willi
  • Schubert, Martin, Alexander

Abstract

A modified release formulation of lacosamide suitable for once-daily administration.

IPC Classes  ?

  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61P 25/08 - AntiepilepticsAnticonvulsants
  • A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

41.

PROCESS FOR PREPARING LACOSAMIDE

      
Application Number EP2011069721
Publication Number 2012/065891
Status In Force
Filing Date 2011-11-09
Publication Date 2012-05-24
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Merschaert, Alain
  • Szczepaniak, Christophe Joseph
  • Hamann, Joerg
  • Kanzler, Ralf

Abstract

The present invention provides a process for the preparation of lacosamide in substantially optically pure form, which in one aspect comprises the following steps: (i) resolution of O-methyl-D,L-serine to provide O-methyl-D-serine in substantially optically pure form; (ii) acetylation of O-methyl-D-serine thereby obtained to provide the N-acetyl 10 derivative thereof in substantially optically pure form; (iii) activating the carboxy group of the compound thereby obtained; and (iv) reacting the compound thereby obtained with benzylamine.

IPC Classes  ?

  • C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
  • C07C 229/22 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
  • C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

42.

PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES

      
Application Number EP2011067038
Publication Number 2012/041986
Status In Force
Filing Date 2011-09-29
Publication Date 2012-04-05
Owner UCB PHARMA GmbH (Germany)
Inventor
  • Merschaert, Alain
  • Bouvy, Didier
  • Vasselin, David
  • Carly, Nicolas

Abstract

The present invention relates to a process of manufacture of compounds of formula (B) wherein R1, R2 and R3 are as defined for compounds of formula (A), which process comprises hydrogenation of compounds of general formula (A). In particular, the present invention relates to an improved process for the manufacture of Lacosamide (LCM), (R)-2-acetamido-N-benzyl-3-methoxypropion-amide (B1), which is useful as an anticonvulsive drug.

IPC Classes  ?

  • C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
  • C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
  • C07C 231/18 - Preparation of optical isomers by stereospecific synthesis
  • C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

43.

NEUPRO

      
Application Number 156648100
Status Registered
Filing Date 2012-02-29
Registration Date 2014-03-25
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 16 - Paper, cardboard and goods made from these materials
  • 40 - Treatment of materials; recycling, air and water treatment,
  • 41 - Education, entertainment, sporting and cultural services

Goods & Services

(1) Pharmaceutical preparations for the treatment of the central nervous system, namely Parkinson's disease and restless legs syndrome (RLS); Printed teaching and course materials, in the field of central nervous system diseases, namely Parkinson's disease and restless legs syndrome (RLS). (1) Distribution of printed publications, newspapers, magazines, books and information materials, in the field of central nervous system diseases, namely Parkinson's disease and restless legs syndrome (RLS); Publication printing and publication of articles in electronic form except for promotional purposes, namely, on the Internet, publishing magazines and books in electronic form, namely, on the Internet, in the field of central nervous system diseases, namely Parkinson's disease and restless legs syndrome (RLS).

44.

PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S) - 5 -ALKOXY- 2 -AMINOTETRALIN DERIVATIVES

      
Application Number EP2011060655
Publication Number 2011/161255
Status In Force
Filing Date 2011-06-24
Publication Date 2011-12-29
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Ates, Célal
  • Schule, Arnaud
  • Palacio, Magali
  • Deutsch, Paul
  • Vasselin, David
  • Carly, Nicolas
  • Phadtare, Ganesh
  • Yerande, Swapnil
  • Delatinne, Jean-Pierre
  • Escudero Hernandez, Maria Luisa
  • Pinilla, Véronique

Abstract

The present invention provides an alternative synthesis of N-substituted aminotetralines comprising resolution of N-substituted aminotetralins of formula (II), wherein R1, R2 and R3 are as defined for compound of formula (I).

IPC Classes  ?

  • C07C 51/41 - Preparation of salts of carboxylic acids by conversion of the acids or their salts into salts with the same carboxylic acid part
  • C07C 59/48 - Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
  • C07C 59/56 - Unsaturated compounds containing hydroxy or O-metal groups containing halogen
  • C07C 59/64 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
  • C07C 213/10 - SeparationPurificationStabilisationUse of additives
  • C07C 217/94 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
  • C07C 269/08 - SeparationPurificationStabilisationUse of additives
  • C07C 271/30 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
  • C07D 209/34 - Oxygen atoms in position 2

45.

Process for the preparation of amino acid derivatives

      
Application Number 13127555
Grant Number 08946476
Status In Force
Filing Date 2009-11-06
First Publication Date 2011-10-27
Grant Date 2015-02-03
Owner UCB Pharma GmbH (Germany)
Inventor
  • Bouvy, Didier
  • Merschaert, Alain
  • Pinilla, Véronique
  • Hamann, Joerg
  • Kanzler, Ralf
  • Thomas, Antoine

Abstract

The present patent application relates to an alternative process for the preparation of amino derivatives. In particular, the present application relates to an improved process for the manufacture of Lacosamide (LCM), (R)-2-acetamido-N-benzyl-3-methoxypropion-amide, which is useful as an anticonvulsive drug. In a particular aspect, the present invention relates to a process of manufacture of optically enriched (R)-2-acetamido-N-benzyl-3-methoxypropion-amide (I) comprising resolution of 2-acetamido-N-benzyl-3-methoxypropion-amide (II).

IPC Classes  ?

  • C07C 231/20 - Preparation of optical isomers by separation of optical isomers
  • C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
  • C07C 231/18 - Preparation of optical isomers by stereospecific synthesis

46.

LACOSAMIDE DETECTION ASSAY

      
Application Number EP2011001843
Publication Number 2011/128079
Status In Force
Filing Date 2011-04-13
Publication Date 2011-10-20
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Boekens, Hilmar
  • Cawello, Willi

Abstract

The present application relates to a method of determining the anticonvulsant drug lacosamide in a body fluid sample, particularly in plasma, serum or saliva using a HPLC-UV method, and a lacosamide analogue as a standard. The present application also relates to a new method of determining the lacosamide content in a mammals body by measuring the lacosamide concentration or amount in the saliva.

IPC Classes  ?

  • G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics
  • G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography

47.

Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof

      
Application Number 13159738
Grant Number 08742140
Status In Force
Filing Date 2011-06-14
First Publication Date 2011-10-06
Grant Date 2014-06-03
Owner UCB Pharma GmbH (Germany)
Inventor Meese, Claus

Abstract

6 alkyl. This compound is a valuable intermediate which may be used in the synthesis of fesoterodine, tolterodine, its active metabolite, and related compounds.

IPC Classes  ?

  • C07D 311/00 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings

48.

NOVEL PROCESS FOR THE PREPARATION OF NITROGEN SUBSTITUTED AMINOTETRALINS DERIVATIVES

      
Application Number EP2011051549
Publication Number 2011/095539
Status In Force
Filing Date 2011-02-03
Publication Date 2011-08-11
Owner UCB PHARMA GmbH (Germany)
Inventor
  • Vasselin, David
  • Carly, Nicolas
  • Ates, Célal

Abstract

The present invention provides an alternative synthesis of N-substituted aminotetralines which synthesis comprises catalytic asymmetric hydrogenation of compounds of general formula (A).

IPC Classes  ?

  • C07C 231/18 - Preparation of optical isomers by stereospecific synthesis
  • C07C 233/23 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring

49.

POLYVINYLPYRROLIDONE FOR THE STABILIZATION OF A SOLID DISPERSION OF THE NON-CRYSTALLINE FORM OF ROTIGOTINE

      
Application Number EP2010070563
Publication Number 2011/076879
Status In Force
Filing Date 2010-12-22
Publication Date 2011-06-30
Owner
  • UCB PHARMA GMBH (Germany)
  • LTS LOHMANN THERAPIE-SYSTEME AG (Germany)
Inventor
  • Wolff, Hans-Michael
  • Arth, Christoph
  • Quere, Luc
  • Müller, Walter

Abstract

The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

IPC Classes  ?

  • A61K 9/70 - Web, sheet or filament bases
  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings

50.

Synthesis scheme for lacosamide

      
Application Number 12961705
Grant Number 08809585
Status In Force
Filing Date 2010-12-07
First Publication Date 2011-06-02
Grant Date 2014-08-19
Owner UCB Pharma GmbH (Germany)
Inventor
  • Riedner, Jens
  • Dunne, Gavin

Abstract

The present invention is concerned with an improved method of producing (R)-2-acetamido-N-benzyl-3-methoxypropionamide (lacosamide) comprising the 0-methylation of a compound of formula (I) to produce a compound of formula (II) in a single step reaction.

IPC Classes  ?

  • C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines

51.

PHARMACEUTICAL COMPOSITION COMPRISING ROTIGOTINE SALTS (ACID OR NA), ESPECIALLY FOR IONTOPHORESIS

      
Application Number EP2010003796
Publication Number 2010/149363
Status In Force
Filing Date 2010-06-24
Publication Date 2010-12-29
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Bouwstra, J.A.
  • Ackaert, O.W.G.M.K.
  • Eikelenboom, J.
  • Wolff, Hans-Michael

Abstract

The present invention relates to new salts of 6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1- ol (rotigotine), their use as a medicament, for example for the treatment of CNS disorders like Parkinson Disease, RLS, fybromyalgia and/or depression, in particular through electromotive administration. The present invention relates to pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of rotigotine to at least one target tissue. The formulations are further characterized by good to excellent solubility of the salts in aqueous solutions.

IPC Classes  ?

  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/70 - Web, sheet or filament bases
  • C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
  • A61P 25/16 - Anti-Parkinson drugs

52.

Polymorphic form of rotigotine and process for production

      
Application Number 12744989
Grant Number 08592477
Status In Force
Filing Date 2008-11-25
First Publication Date 2010-12-09
Grant Date 2013-11-26
Owner UCB Pharma GmbH (Germany)
Inventor
  • Wolff, Hans-Michael
  • Quere, Luc
  • Riedner, Jens

Abstract

α irradiation (1.54060), and a process for production thereof, which is useful for the manufacture of a stable medicament for treating or alleviating symptoms of Parkinson's Disease and other dopamine-related disorders.

IPC Classes  ?

  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

53.

Anticonvulsant combination therapy

      
Application Number 12304023
Grant Number 08735356
Status In Force
Filing Date 2007-06-15
First Publication Date 2010-09-23
Grant Date 2014-05-27
Owner UCB Pharma GmbH (Germany)
Inventor Stoehr, Thomas

Abstract

A pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation and/or treatment of epileptic seizures.

IPC Classes  ?

  • A61K 31/19 - Carboxylic acids, e.g. valproic acid
  • A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
  • A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof

54.

Accelerated synthesis of substituted hydroxymethyl phenols

      
Application Number 12303660
Grant Number 08299306
Status In Force
Filing Date 2007-06-04
First Publication Date 2010-07-08
Grant Date 2012-10-30
Owner UCB MANUFACTURING IRELAND LIMITED (Ireland)
Inventor
  • Ennis, Seth C.
  • Kennedy, Bryan D.

Abstract

6 alkyl group, and preferably a methyl group, and then further reacting the compound of formula (IV) in a known manner to obtain a compound of formula (I) and optionally salt formation.

IPC Classes  ?

  • C07C 211/00 - Compounds containing amino groups bound to a carbon skeleton

55.

PATCH PRODUCTION TECHNOLOGY

      
Application Number EP2009009207
Publication Number 2010/075992
Status In Force
Filing Date 2009-12-22
Publication Date 2010-07-08
Owner UCB PHARMA GMBH (Germany)
Inventor Jasch, Ingolf

Abstract

The invention relates to a transdermal, especially dopaminergic patch, comprising a release liner film, an active substance layer, and a carrier film, wherein the active substance layer is applied between the release liner film and the carrier film. The release liner film and/or the carrier film thereby comprise at least one separation edge brought about thermally, at least partially defining a peripheral edge of the patch. The invention further relates to a method for producing such a transdermal patch and to a tool for producing the patch according to the method according to the invention. Crystal growth in the active substance layer can be reliably prevented by the patch according to the invention.

IPC Classes  ?

  • A61K 9/70 - Web, sheet or filament bases
  • A61F 13/02 - Adhesive bandages or dressings
  • B26F 1/20 - Perforating by slitting, i.e. forming cuts closed at their ends without removal of material with tools carried by a rotating drum or similar support
  • B26F 1/38 - Cutting-outStamping-out
  • B26F 3/10 - Severing by using heat with heated members with heated rollers or discs

56.

Pharmaceutical compositions comprising fesoterodine

      
Application Number 12692063
Grant Number 08501723
Status In Force
Filing Date 2010-01-22
First Publication Date 2010-05-27
Grant Date 2013-08-06
Owner UCB Pharma GmbH (Germany)
Inventor
  • Mika, Hans-Jürgen
  • Arth, Christoph
  • Komenda, Michael
  • Bicane, Fatima
  • Paulus, Kerstin
  • Irngartinger, Meike
  • Lindner, Hans

Abstract

The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.

IPC Classes  ?

  • A01N 43/00 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N 37/02 - Saturated carboxylic acids or thio-analogues thereofDerivatives thereof
  • A61K 31/33 - Heterocyclic compounds
  • A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K 9/14 - Particulate form, e.g. powders

57.

NOVEL PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES

      
Application Number EP2009007962
Publication Number 2010/052011
Status In Force
Filing Date 2009-11-06
Publication Date 2010-05-14
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Bouvy, Didier
  • Merschaert, Alain
  • Pinilla, Véronique
  • Hamann, Joerg
  • Kanzler, Ralf
  • Thomas, Antoine

Abstract

The present patent application relates to an alternative process for the preparation of amino derivatives. In particular, the present application relates to an improved process for the manufacture of Lacosamide (LCM), (R)-2-acetamido-N-benzyl-3-methoxypropion-amide, which is useful as an anticonvulsive drug. In a particular aspect, the present invention relates to a process of manufacture of optically enriched (R)-2-acetamido-N-benzyl-3-methoxypropion-amide (I) comprising resolution of 2-acetamido-N-benzyl-3-methoxypropion-amide (II).

IPC Classes  ?

  • C07C 231/20 - Preparation of optical isomers by separation of optical isomers
  • C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
  • C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C 237/52 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the nitrogen atom of at least one of the carboxamide groups further acylated

58.

Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof

      
Application Number 12304323
Grant Number 07982058
Status In Force
Filing Date 2007-06-06
First Publication Date 2009-07-30
Grant Date 2011-07-19
Owner UCB Pharma GmbH (Germany)
Inventor Meese, Claus

Abstract

6 alkyl. This compound is a valuable intermediate which may be used in the synthesis of fesoterodine, tolterodine, its active metabolite, and related compounds.

IPC Classes  ?

  • C07D 311/00 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings

59.

Neupro

      
Application Number 1003483
Status Registered
Filing Date 2009-02-14
Registration Date 2009-02-14
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 16 - Paper, cardboard and goods made from these materials
  • 41 - Education, entertainment, sporting and cultural services

Goods & Services

Pharmaceutical products and substances used to treat diseases of the central nervous system. Printed teaching and course materials for physicians and pharmacists. Publication printing and publication of articles in electronic form (except for promotional purposes), including on the Internet, publishing magazines and books in electronic form, including on the Internet.

60.

Polymorphic form of rotigotine and process for production

      
Application Number 12324166
Grant Number 08232414
Status In Force
Filing Date 2008-11-26
First Publication Date 2009-06-04
Grant Date 2012-07-31
Owner UCB Pharma GmbH (Germany)
Inventor
  • Wolff, Hans-Michael
  • Quere, Luc
  • Riedner, Jens

Abstract

α irradiation (1.54060 Å), and a process for production thereof, which is useful for the manufacture of a stable medicament for treating or alleviating symptoms of Parkinson's disease and other dopamine-related disorders.

IPC Classes  ?

  • C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

61.

NOVEL POLYMORPHIC FORM OF ROTIGOTINE AND PROCESS FOR PRODUCTION

      
Document Number 02703561
Status In Force
Filing Date 2008-11-25
Open to Public Date 2009-06-04
Grant Date 2016-01-19
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Wolff, Hans-Michael
  • Quere, Luc
  • Riedner, Jens

Abstract

The present invention relates to a novel polymorphic form of Rotigotine characterized by at least one of the following X- ray powder diffraction peaks: 12.04, 13.68, 17.72 and 19.01 ~ 0.2 (°20), measured with a Cu-K .alpha. irradiation (1.54060 A), and a process for production thereof, which is useful for the manufacture of a stable medicament for treating or alleviating symptoms of Parkinson's Disease and other dopamine-related disorders.

IPC Classes  ?

  • C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61P 25/00 - Drugs for disorders of the nervous system

62.

POLYMORPHIC FORM OF ROTIGOTINE

      
Application Number EP2008066137
Publication Number 2009/068520
Status In Force
Filing Date 2008-11-25
Publication Date 2009-06-04
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Wolff, Hans-Michael
  • Quere, Luc
  • Riedner, Jens

Abstract

The present invention relates to a novel polymorphic form of Rotigotine characterized by at least one of the following X- ray powder diffraction peaks: 12.04, 13.68, 17.72 and 19.01 ± 0.2 (°2θ), measured with a Cu-Kα irradiation (1.54060 Å), and a process for production thereof, which is useful for the manufacture of a stable medicament for treating or alleviating symptoms of Parkinson's Disease and other dopamine-related disorders.

IPC Classes  ?

  • C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61P 25/00 - Drugs for disorders of the nervous system

63.

Pharmaceutical compositions comprising fesoterodine

      
Application Number 12342744
Grant Number 08088398
Status In Force
Filing Date 2008-12-23
First Publication Date 2009-05-07
Grant Date 2012-01-03
Owner UCB Pharma GmbH (Germany)
Inventor
  • Mika, Hans-Jürgen
  • Arth, Christoph
  • Komenda, Michael
  • Bicane, Fatima

Abstract

The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.

IPC Classes  ?

  • A01N 37/02 - Saturated carboxylic acids or thio-analogues thereofDerivatives thereof
  • A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K 9/14 - Particulate form, e.g. powders

64.

COMPOUNDS FOR TREATING DEMYELINATION CONDITIONS

      
Application Number EP2008008969
Publication Number 2009/053070
Status In Force
Filing Date 2008-10-23
Publication Date 2009-04-30
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Stöhr, Thomas
  • Rudd, David

Abstract

Therapeutic methods, therapeutic combinations and pharmaceutical compositions provided herein are useful for inhibiting demyelination, for delaying the clinical onset of a demylination condition, for inhibiting progression and/or reducing frequency of relapse of a demylination condition, and/or enhancing physical ability of a human subject having a demylination condition. Lacosamide is one of the active compounds.

IPC Classes  ?

  • A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

65.

NEUPRO

      
Serial Number 79069118
Status Registered
Filing Date 2009-02-14
Registration Date 2010-03-23
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 16 - Paper, cardboard and goods made from these materials
  • 41 - Education, entertainment, sporting and cultural services

Goods & Services

Pharmaceutical preparations and substances for the treatment of diseases of the central nervous system Printed teaching and educational materials in the field of the central nervous system for use by physicians and pharmacists [ Electronic publishing services, namely, publication of articles of others on CD, DVD, and online featuring central nervous system diseases; publication of magazines and books ]

66.

Miscellaneous Design

      
Application Number 990265
Status Registered
Filing Date 2008-09-30
Registration Date 2008-09-30
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations and substances for the treatment of central nervous system diseases.

67.

Pharmaceutical compositions comprising fesoterodine

      
Application Number 11811327
Grant Number 07807715
Status In Force
Filing Date 2007-06-07
First Publication Date 2008-06-12
Grant Date 2010-10-05
Owner UCB Pharma GmbH (Germany)
Inventor
  • Arth, Christoph
  • Komenda, Michael
  • Bicane, Fatima
  • Mika, Hans-Jurgen

Abstract

The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.

IPC Classes  ?

  • A01N 37/02 - Saturated carboxylic acids or thio-analogues thereofDerivatives thereof
  • A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K 9/14 - Particulate form, e.g. powders

68.

Neupro 4mg

      
Application Number 006762348
Status Registered
Filing Date 2008-03-07
Registration Date 2008-12-17
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 16 - Paper, cardboard and goods made from these materials
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations and substances for treating the central nervous system. Printed information publications, namely brochures and newsletters about central nervous system diseases. Pharmaceutical consultancy regarding application and/or use of medicines for treatment of central nervous system diseases.

69.

Neupro 2mg

      
Application Number 006762355
Status Registered
Filing Date 2008-03-07
Registration Date 2008-12-10
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 16 - Paper, cardboard and goods made from these materials
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations and substances for treating the central nervous system. Printed matter for information purposes, namely magazines, brochures and newsletters relating to disorders of the central nervous system. Pharmaceutical consultancy on the use of medicines and/or sanitary preparations in treating disorders of the central nervous system.

70.

Neupro 8mg

      
Application Number 006762322
Status Registered
Filing Date 2008-03-07
Registration Date 2008-12-10
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 16 - Paper, cardboard and goods made from these materials
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations and substances for treating the central nervous system. Printed matter for information purposes, namely magazines, brochures and newsletters relating to disorders of the central nervous system. Pharmaceutical consultancy on the use of medicines and/or sanitary preparations in treating disorders of the central nervous system.

71.

Neupro 6mg

      
Application Number 006762331
Status Registered
Filing Date 2008-03-07
Registration Date 2008-12-10
Owner UCB Pharma GmbH (Germany)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 16 - Paper, cardboard and goods made from these materials
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceutical preparations and substances for treating the central nervous system. Printed information publications, namely brochures and newsletters about central nervous system diseases. Pharmaceutical consultancy regarding application and/or use of medicines for treatment of central nervous system diseases.

72.

STABILIZED PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE

      
Document Number 02652712
Status In Force
Filing Date 2007-06-06
Open to Public Date 2007-12-13
Grant Date 2014-04-01
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Arth, Christoph
  • Mika, Hans-Juergen
  • Komenda, Michael
  • Lindner, Hans
  • Bicane, Fatima
  • Paulus, Kerstin
  • Irngartinger, Meike

Abstract

The present application relates to a pharmaceutical composition comprising fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a stabilizer selected from the group consisting of xylitol, sorbitol, polydextrose, isomalt and dextrose.

IPC Classes  ?

  • A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61P 13/10 - Drugs for disorders of the urinary system of the bladder

73.

Neupro

      
Application Number 906162
Status Registered
Filing Date 2006-10-31
Registration Date 2006-10-31
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations and substances for the treatment of central nervous system diseases.

74.

DAVISTO

      
Application Number 885993
Status Registered
Filing Date 2006-03-30
Registration Date 2006-03-30
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations and substances.

75.

Transdermal administration of (R)-3,3-diphenylpropylamin-monoesters

      
Application Number 10533683
Grant Number 07670621
Status In Force
Filing Date 2004-04-03
First Publication Date 2006-02-09
Grant Date 2010-03-02
Owner UCB PHARMA GMBH (Germany)
Inventor
  • Breitenbach, Armin
  • Meese, Claus
  • Wolff, Hans-Michael
  • Drews, Roland

Abstract

1-3alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.

IPC Classes  ?

76.

LEGANTO

      
Application Number 865001
Status Registered
Filing Date 2005-08-03
Registration Date 2005-08-03
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations and substances.

77.

LEGANTO

      
Application Number 004495181
Status Registered
Filing Date 2005-06-16
Registration Date 2006-04-20
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations containing the active substance rotigotine for treating restless leg syndrome, in the form of plasters, as well as Parkinson's disease.

78.

Miscellaneous Design

      
Application Number 844830
Status Registered
Filing Date 2004-11-10
Registration Date 2004-11-10
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations and substances for the treatment of central nervous system diseases.

79.

Transdermal delivery system for the administration of rotigotine

      
Application Number 10623864
Grant Number 08246979
Status In Force
Filing Date 2003-07-22
First Publication Date 2005-04-14
Grant Date 2012-08-21
Owner UCB Pharma GmbH (Germany)
Inventor
  • Schacht, Dietrich Wilhelm
  • Hannay, Mike
  • Wolff, Hans-Michael

Abstract

An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains rotigotine in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of rotigotine and is impermeable to the protonated form of rotigotine.

IPC Classes  ?

  • A61F 13/00 - Bandages or dressingsAbsorbent pads
  • A61F 13/02 - Adhesive bandages or dressings
  • A61K 9/70 - Web, sheet or filament bases
  • A61L 15/16 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons

80.

Neupro

      
Application Number 003143328
Status Registered
Filing Date 2003-04-24
Registration Date 2004-04-21
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations and substances for treating the central nervous system.

81.

NEUPRO

      
Serial Number 76492893
Status Registered
Filing Date 2003-02-25
Registration Date 2004-04-27
Owner UCB PHARMA GMBH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

PHARMACEUTICAL PREPARATIONS AND SUBSTANCES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES, SOLD UNDER PRESCRIPTION ONLY

82.

NEUPRO

      
Application Number 740032
Status Registered
Filing Date 2000-08-21
Registration Date 2000-08-21
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical products.

83.

NEUPRO

      
Application Number 107761600
Status Registered
Filing Date 2000-10-04
Registration Date 2007-02-20
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Pharmaceutical preparations and substances for the treatment of central nervous system diseases, heart and circulatory diseases, urological disorders, sold under prescription only

84.

Miscellaneous Design

      
Application Number 675469A
Status Registered
Filing Date 1997-05-28
Registration Date 1997-05-28
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Médicaments, produits chimiques pour la médecine et l'hygiène, drogues pharmaceutiques.

85.

SCHWARZ PHARMA

      
Application Number 653635
Status Registered
Filing Date 1996-03-08
Registration Date 1996-03-08
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Medicines, chemical products for medical and sanitary use, pharmaceutical drugs.

86.

MOEX

      
Application Number 625486A
Status Registered
Filing Date 1994-09-09
Registration Date 1994-09-09
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Produits pharmaceutiques, vétérinaires et hygiéniques; substances diététiques à usage médical, aliments pour bébés; emplâtres, matériel pour pansements; matières pour plomber les dents et pour empreintes dentaires; désinfectants; produits pour la destruction des animaux nuisibles; fongicides, herbicides.

87.

NITROPLAST

      
Application Number 502956
Status Registered
Filing Date 1986-05-16
Registration Date 1986-05-16
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Médicaments pour le traitement des maladies cardiovasculaires.

88.

dehydro sanol

      
Application Number 294522
Status Registered
Filing Date 1965-02-23
Registration Date 1965-02-23
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Médicaments, produits chimiques pour la médecine et l'hygiène, drogues pharmaceutiques.

89.

spasmo-gallo-sanol

      
Application Number 423051
Status Registered
Filing Date 1976-06-24
Registration Date 1976-06-24
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Médicaments, produits chimiques pour la médecine et l'hygiène, drogues pharmaceutiques.

90.

FERROSANOL

      
Application Number 181223
Status Registered
Filing Date 1954-12-06
Registration Date 1954-12-06
Owner UCB Pharma GmbH (Germany)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Medicines.